Our vision is to market an insulin-independent treatment to help T2D patients live a life free from diabetes symptoms and complications.
Available treatments fall short. Presently, there are several different classes of T2D drugs approved by the FDA, drugs that lose their effectiveness over time. The great majority of them involve modulation of insulin production and sensitivity, the very systems that are dysfunctional in T2D. Our groundbreaking solution has the advantage of a unique pathway that does not target the insulin pathway.
our approach to T2D treatment
Studies in type 2 diabetic animal models have demonstrated that Atrogi’s lead drug candidate ATR-258 lowers blood glucose to healthy levels independent of insulin. In addition, the drug candidate enhances insulin sensitivity and lowers insulin production. The treatment can potentially function as a stand-alone or a combination therapy.
Atrogi’s concept is scientifically and commercially innovative, as it lowers blood glucose levels without involving insulin, thus offering an unprecedented approach to the treatment of T2D.
- Distinctive pathway – The small molecules promote increased glucose uptake into skeletal muscles independent of insulin
- A family of patentable small molecules – Our compounds have unique and desirable characteristics needed for drug development
- Minimal side effects – We can modulate our molecules to activate their target with minimal side-effects
Unique mode of action through GLUT4 translocation
The skeletal muscle is the biggest and most important organ when it comes to lowering blood glucose levels. Atrogi’s compound binds to a specific receptor on the skeletal muscle surface, and induces an intracellular signaling pathway, which leads to translocation of glucose transporter 4 (GLUT4) to the cell surface. There, it transports glucose from the bloodstream into the muscle cell, thus lowering blood glucose back to healthy levels.